Novavax (NASDAQ:NVAX) received a $2.00 price objective from investment analysts at Cantor Fitzgerald in a research report issued on Monday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 15.45% from the stock’s previous close.

NVAX has been the topic of a number of other reports. B. Riley set a $10.00 target price on shares of Novavax and gave the company a “buy” rating in a research report on Monday, October 8th. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. JPMorgan Chase & Co. upgraded shares of Novavax from an “underweight” rating to an “overweight” rating and upped their target price for the company from $2.00 to $2.25 in a research report on Friday, September 21st. Finally, BidaskClub upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, November 3rd. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $3.37.

NASDAQ:NVAX traded down $0.09 during mid-day trading on Monday, reaching $1.73. 2,542,774 shares of the company were exchanged, compared to its average volume of 5,446,717. Novavax has a 12 month low of $1.05 and a 12 month high of $2.75. The firm has a market cap of $696.79 million, a P/E ratio of -2.75 and a beta of 2.51.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $9.63 million. During the same period in the prior year, the company earned ($0.15) EPS. The firm’s revenue was down 8.3% compared to the same quarter last year. As a group, analysts expect that Novavax will post -0.5 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. acquired a new stake in shares of Novavax in the 3rd quarter valued at approximately $113,000. Regentatlantic Capital LLC acquired a new stake in shares of Novavax in the 2nd quarter valued at approximately $107,000. Xact Kapitalforvaltning AB raised its position in shares of Novavax by 40.3% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 100,700 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 28,900 shares during the period. SG Americas Securities LLC raised its position in shares of Novavax by 388.4% in the 2nd quarter. SG Americas Securities LLC now owns 102,003 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 81,117 shares during the period. Finally, Paloma Partners Management Co acquired a new stake in shares of Novavax in the 3rd quarter valued at approximately $256,000. Institutional investors own 42.07% of the company’s stock.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.

Featured Story: Fundamental Analysis and Choosing Stocks

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.